Company intelligence / Profile preview
Wuhan Healthgen Biotechnology Corp.
Wuhan, Hubei, Chinaoryzogen.net ↗
- Ownership
- Private
- Employees
- ~100
- Development stage
- Phase 3
01
Overview
Wuhan Healthgen Biotechnology has completed Phase III trials for its plant-derived recombinant human serum albumin (OsrHSA) in patients with hypoalbuminemia due to liver cirrhosis. The product demonstrated non-inferior efficacy and safety compared to plasma-derived HSA. A new drug application will be submitted in 2024–2025 with expected market launch as early as next year. This would be the world’s first commercial plant-made recombinant human serum albumin approved for clinical use.
- Therapeutic areas
- EndocrinologyImmunologyOtherDermatologyGastroenterologyNeurologyInfectious Diseases
- Modalities
- Recombinant proteinsenzymespeptides
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
Collaborations with biotechnology and pharmaceutical companies for custom expression services using their platform technologyNational Science and Technology Major Project for New Drug Development support from Chinese government agencies
Beyond the preview
Go deeper on Wuhan Healthgen Biotechnology Corp..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Wuhan Healthgen Biotechnology Corp..